OR WAIT null SECS
(July 7, 2009; NEWARK, DE)
, a leading full-service GLP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced today its strategic alliance with
Taiwan’s Development Center for Biotechnology
(DCB) . DCB is a non-profit organization supported primarily by government funding to advance Taiwan biotech industry and serve as a bridge between Taiwan and the rest of the world.
This strategic alliance leverages the strengths of both organizations and gives biopharmaceutical companies access to a complete range of drug development services from preclinical through clinical services. In conjunction with DCB, QPS’ current services will be expanded into chemistry, manufacturing and controls (CMC),
in vitro/in vivo
toxicology, and pharmacology. It is noteworthy that the recently passed
Taiwan Biotechnology Takeoff Package
has also paved the way for the expansion of DCB’s services to cover process development and cGMP production of biopharmaceuticals.
“QPS currently operates a state-of-the-art, bioanalytical LC/MS/MS facility in Taipei, Taiwan. Our partnership with DCB provides QPS with access to enhanced service offerings, not only to our clients in the Asia-Pacific Rim region, but around the world,” stated QPS CEO and Founder, Ben Chien, Ph.D. “We now have the ability to expand our services to cover preclinical through clinical with even more efficiencies of scale—to increase speed and reduce costs while maintaining our focus on accuracy of data. As with QPS, the DCB has a strong history and reputation with providing valuable and accurate services.”
“DCB now positions itself as a “preclinical value-adding R&D center for biopharmaceuticals” in Taiwan’s drug development value-chain. Our organization has been collaborating with QPS on a project-by-project basis. The new strategic alliance with QPS will not only provide complete and integrated international-standard preclinical testing services to domestic and pharmaceutical companies, but also lead to new clients and expanded business opportunities for DCB in the international drug development arena. We believe this will bring us one step closer to realizing our vision of becoming an internationally outstanding preclinical research and service institute for biopharmaceutical development,” stated DCB President, Dr. Chia-Lin Jeff Wang.
QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of bioanalysis, preclinical DMPK, translational medicine research, and early-phase clinical research. Our regional laboratories are located at Newark, Delaware; Springfield, Missouri; and Taipei, Taiwan.
About Development Center for Biotechnology
The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization established in 1984 with the support of the Department of Industrial Technology (DOIT), Ministry of Economic Affairs (MOEA). Our main mission is to help shape and develop Taiwan’s biotechnology industry through R&D, infrastructure-building and training programs.